

## Oral 1821- 2 - Decreased systemic tetrahydrobiopterin bioavailability and increased oxidized biopterins in children with cerebral malaria

<http://dx.doi.org/10.1016/j.niox.2014.09.021>

Matthew P. Rubacha,<sup>b</sup> J. Brice Weinberga,<sup>b</sup> Jackson Mukemba <sup>c</sup>, Salvatory Florence <sup>c</sup>, Bert K. Lopansri <sup>d,e</sup>, Keith Hyland <sup>f</sup>, Alicia D. Volkheimera,<sup>b</sup>, Tsin W. Yeog,<sup>h,i</sup>, Nicholas M Anstey <sup>g</sup>, <sup>h,i</sup>, Esther D. Mwaikambo <sup>c</sup>, Donald L. Granger <sup>j,k</sup>

a Department of Medicine, Duke University, Durham, NC, USA

b VA Medical Centers, Durham, NC, USA

c Department of Pediatrics, Hubert Kairuki Memorial University, Dar es Salaam, United Republic of Tanzania

d Department of Medicine, Intermountain Healthcare, Salt Lake City, UT, USA

e University of Utah, Salt Lake City, UT, USA

f Medical Neurogenetics, Atlanta, GA, USA

g Global and Tropical Health Division, Menzies School for Health Research, Darwin, Australia

h Charles Darwin University, Darwin, Australia

i Division of Medicine, Royal Darwin Hospital, Darwin, NT, Australia

j Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

k VA Medical Center, Salt Lake City, UT, USA

**Background:** Falciparum malaria causes over 600,000 deaths worldwide each year. Despite advances in anti-parasitic drug therapies, 10–20% of children treated for severe malaria die. We have previously documented that NO protects against development of severe malaria, and that NO levels are low in malaria patients. Tetrahydrobiopterin (BH4) is an enzyme co-factor required for NO synthase that converts L-arginine to NO. Low or absent BH4 results in superoxide (instead of NO) production by NOS, with a consequent increase in “oxidative stress.”

**Hypothesis:** Systemic levels of BH4 are decreased in children with cerebral malaria, contributing to low NO bioavailability and increased severity of malaria.

Objective: Determine systemic levels of BH4 in children with malaria.

**Methods:** In an observational study in Tanzania, we measured urine levels of biopterin in its various redox states [fully reduced biopterin (BH4), and the oxidized metabolites dihydrobiopterin (BH2) and biopterin (B0)] in children with un-complicated malaria (UM, n=55), cerebral malaria

(CM, n=46), as well as control children with non-malaria central nervous system conditions (NMC, n=48) and healthy control children (HC, n=111). Urine was collected into dithioerythritol and diethylene triamine penta-acetic acid (DETAPAC). Pterins were measured by high-performance liquid chromatography using sequential electrochemical and fluorescence detection.

**Results:** Urine BH<sub>4</sub> concentrations [ $\mu\text{mol}/\text{mmol}$  creatinine; median (IQR)] in CM were significantly lower compared to those in children in each of the other three groups. Oxidized biopterin were increased, and the BH<sub>4</sub>:BH<sub>2</sub> ratio was markedly reduced in CM. Blood mononuclear cell guanosine triphosphate cyclohydrolase I mRNA was not low in any of the groups compared to the HC children. In a multivariate logistic regression model, each unit decrease in urine BH<sub>4</sub> was independently associated with a 3.85 (95% CI: 1.89–7.69) fold increase in odds of CM ( $p < 0.001$ ).

**Conclusions:** Low systemic BH<sub>4</sub> levels and increased oxidized biopterins likely contribute to the low NO bioavailability observed in cerebral malaria. Adjunctive interventions to increase BH<sub>4</sub> may reduce occurrence of severe falciparum malaria in children.

**Keywords:** Malaria; Tetrahydrobiopterin; BH<sub>4</sub>; Nitric oxide.